Year-end report 2018 Bactiguard Holding AB
2018 was an exciting and eventful year for Bactiguard when we reached several important milestones, primarily strong growth in sales of our own product portfolio for infection prevention (BIP portfolio), the distribution and license agreement with Well Lead for China and the CE mark for orthopaedic trauma implants, which opens possibilities in a completely new application area for Bactiguard's technology.Fourth quarter (October-December 2018) · Revenues amounted to SEK 42.1 (41.4) million, an increase of 2% driven by higher BIP sales, while new license revenues were lower than previous